27
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Neurochemical Aspects of Depression: The Past and the Future?

&
Pages 19-47 | Received 08 Nov 1984, Published online: 07 Jul 2009

References

  • Aghajanian G. K. Central noradrenergic neurons: A locus for the functional interplay between alpha-2 adrenoceptors and opiate receptors. Journal of Clinical Psychiatry 1982; 43: 20–24
  • Agnoli A., Andreoli V., Casacchia M., Cerbo R. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. Journal of Psychiatric Research 1976; 13: 43–54
  • Akiskal H. S., McKinney W. T., Jr. Depressive Disorders: Toward a unified hypothesis. Science 1973; 182: 20–29
  • Albouz S., Hauw J. J., Berwald-Netter Y., Boutry J. M., Bourdon R., Baumann N. Tricyclic antidepressants induce sphingomyleinase deficiency in fibroblast and neuroblastoma cell cultures. Biomedicine 1981; 35: 218–220
  • Altman N., Sachar E. J., Gruen P. H., Halpern F. S., Eto S. Reduced plasma LH concentration in postmenopausal depressed women. Psychosomatic Medicine 1975; 37: 274–276
  • Anden N. E., Grabowska M., Strombom U. Different alpha- adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents. Naunyn-Schmiedeberg's Archives for Pharmacology 1976; 292: 43–52
  • Antelman S. M., Chiodo L. A. Dopamine autoreceptor subsensitivity. A mechanism common to the treatment of depression and induction of amphetamine psychosis ?. Biological Psychiatry 1981; 16: 717–727
  • Asberg M., Thoren P., Traskman L. Serotonin depression: A biochemical subgroup within the affective disorders?. Science 1976; 191: 478–480
  • Axelrod J. Pre- and postsynaptic regulation of catecholamine neurotransmitters. Advances in pharmacology and therapeutics, P. Simon. Pergamon Press, New York 1979; 2: 249–262
  • Ayd F. A preliminary report on Marsilid. American Journal of Psychiatry 1957; 114: 459
  • Baer L., Durell J., Bunney W. E., Levy B. S., Gardon P. V. Sodium-22 retention and 17-hydroxycorticosteroid excretion in affective disorders. A preliminary report. Journal of Psychiatric Research 1969; 6: 289–297
  • Baldessarini R. J. Biogenic amine hypothesis in affective disorders. The nature and treatment of depression, F. F. Flack, S. C. Draghi. John Wiley & Sons, New York 1975; 347–385
  • Banerjee S. P., Kung L. S., Figgi S. J., Chanda S. K. Development of β-adrenergic receptor subsensitivity by antidepressants. Nature 1977; 268: 455–456
  • Baraldi M., Poggioli R., Santi M., Vergoni A. V., Bertolini A. Antidepressants and opiate interactions: Pharmacological and biochemical evidences. Pharmacological Research Communications 1983; 15: 843–857
  • Barchas J. D., Akil H., Elliott G. R., Holman R. B., Watson S. J. Behavioral neurochemistry: Neuroregulators and behavioral states. Science 1978; 200: 964–973
  • Bergstrom D. A., Kellar K. J. Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment. Journal of Pharmacology and Experimental Therapeutics 1979; 209: 256–261
  • Biegon A., Samuel D. The in vivo distribution of an antidepressant drug (DMI) in male and female rats. Psychopharmacology 1979; 65: 259–263
  • Biegon A., Samuel D. Interaction of tricyclic antidepressants with opiate receptors. Biochemical Pharmacology 1980; 29: 460–462
  • Billingsley M. L., Velletri P. A., Roth R. H., DeLorenzo R. J. Carboxylmethylation of calmodulin inhibits phosphorylation in rat membranes and cytosol. Journal of Biological Chemistry 1983; 258: 5352–5357
  • Bloom F. E., Baetge G., Deyo S., Ettenberg A., Koda L., Magistretti P. J., Shoemaker W. J., Staunton D. A. Chemical and physiological aspects of the actions of lithium and antidepressant drugs. Neuropharmacology 1983; 22: 359–365
  • Bonnet K. A. Adaptive alterations in receptor mediated processes and their implications for some mental disorders. Modulators, mediators and specifiers in brain function, Y. H. Ehrlich, J. Volavka, L. G. Davis, E. G. Brunngraber. Plenum Press, New York 1979; 247–256
  • Borbe H. O., Zube I. The detection of specific (3H)-imipramine binding in bovine retina. Brain Research 1983; 264: 178–180
  • Briley M. S., Langer S. Z., Raisman R., Sechter D., Zarifian E. Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science 1980; 209: 303–305
  • Briley M., Langer S. Z., Sette M. Allosteric interaction between the 3H-imipramine binding site and the serotonin uptake mechanism. British Journal of Pharmacology 1981; 74: 817P–818P
  • Brodie B. B., Pletscher A., Shore P. A. Evidence that serotonin has a role in brain function. Science 1955; 122: 968
  • Brodie B. B., Pletscher A., Shore P. A. Possible role of serotonin in brain function and in reserpine action. Journal of Pharmacology and Experimental Therapeutics 1956; 116: 9, (Abst.)
  • Brodie B. B., Spector S., Shore P. A. Interaction of drugs with norepinephrine in the brain. Pharmacological Reviews 1959a; 11: 548–564
  • Brodie B. B., Spector S., Shore P. A. Interaction of monoamine oxidase inhibitors with physiological and biochemical mechanisms in brain. Annals of the New York Academy of Science 1959b; 80: 609–614
  • Brown G. L., Ebert M. H., Goyer P. F., Jimerson D. C, Klein W. J., Bunney W. E., Goodwin F. K. Aggression, suicide and serotonin: Relationships to CSF amine metabolites. American Journal of Psychiatry 1982; 139: 741–746
  • Brunello N., Barbaccia M. L., Chuang D.-M., Costa E. Down- regulation of β-adrenergic receptors following repeated injections of desmethylimipramine: Permissive role of serotonergic axons. Neuropharmacology 1982; 21: 1145–1149
  • Buchsbaum M. S., Haler R. J., Murphy D. L. Suicide attempts, platelet monoamine oxidase and the average evoked response. Acta Psychiatric Scandinavica 1977; 56: 69–79
  • Bunney B. S., De Riemer S. Effect of clonidine on dopaminergic neuron activity in the substantia nigra: Possible indirect mediation of noradrenergic regulation of the serotonergic raphe system. Gilles de la Tourette syndrome, A. J. Friedhoff, T. N. Chase. Raven Press, New York 1982; 99–104
  • Bunney W. E., Jr, Davis J. M. Norepinephrine in depressive reactions: A review. Journal of Psychiatry 1965; 13: 285–305
  • Bunney W. E., Jr., Garland B. L. Selected aspects of amine and receptor hypothesis of affective illness. Journal of Clinical Psychopharmacology 1981; 1: 3–11, (Supplement)
  • Burt D. R., Creese I., Snyder S. H. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 1977; 196: 326–328
  • Cade J. F. J. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 1949; 2: 349–352
  • Cannon W. B., Rosenbleuth A. The supersensitivity of denervated structures. Mac-Millan, New York 1949
  • Carlsson A., Lindquist M., Magnusson T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryp-tophan as reserpine antagonists. Nature 1957; 180: 1200
  • Carman J. S., Wyatt R. J. Calcium: Bivalent cation in the bivalent psychosis. Biological Psychiatry 1979a; 14: 295–336
  • Carman J. S., Wyatt R. J. Calcium: Pace setting the periodic psychoses. American Journal of Psychiatry 1979b; 3: 1035–1039
  • Carpenter W. T., Bunney W. E. Behavioral effects of Cortisol in man. Seminars in Psychiatry 1971; 3: 421–434
  • Carroll B. J., Curtis G. C., Mendels J. Neuroendocrine regulation in depression: I Limbic system-adrenocortical dysfunction. Archives of General Psychiatry 1976; 33: 1039–1044
  • Carroll B. J. Psychiatric disorders and steroids. Neuro-regulators and psychiatric disorders, E. Usdin, D. A. Hamburg, J. D. Barchas. Oxford University Press, New York 1977; 276–283
  • Cerletti U., Bini L. L'elettroshock. Archives of General Neurology and Psychiatry and Psychoanalysis 1938; 19: 226
  • Chan-Palay V. Gamma-aminobutyric acid pathways in the cerebellum studied by retrograde and anterograde transport of glutamic acid decarboxylase (GAD) antibody after in vivo injections. Progress in Brain Research 1982; 55: 51–76
  • Chamey D. S., Heninger G. R., Sternberg D. E., Redmond D. E., Leckman J. F., Maas J. W., Roth R. H. Presynaptic adrenergic receptor sensitivity in depression. Archives of General Psychiatry 1981a; 38: 1334–1340
  • Chamey D. S., Menkes D. B., Heninger G. R. Receptor sensitivity and mechanism of action of antidepressant treatment. Archives of General Psychiatry 1981b; 38: 1160–1180
  • Chamey D. S., Heninger G. R., Sternberg D. E. Serotonin function and mechanism of action of antidepressant treatment. Archives of General Psychiatry 1984; 41: 359–365
  • Chauhan V. P., Kalra V. K. Effect of phospholipid methylation on calcium transport and (Ca++ + Mg++)-ATPase activity in kidney cortex basolateral membranes. Biochimica et Biophysica Acta 1983; 727: 185–195
  • Chin J. H., Goldstein D. B. Electron paramagnetic resonance studies of ethanol on membrane fluidity. Advances in Experimental Medicine and Biology 1977; 85: 111–122
  • Chin J. H., Parsons L. M., Goldstein D. B. Increased cholesterol content of erythrocyte and brain membranes in ethanol-tolerant mice. Biochimica et Biophysica Acta 1978; 513: 358–363
  • Chiodo L. A., Antelman S. M. Repeated tricyclics induce a progressive dopamine autoreceptor sub-sensitivity independent of daily drug treatment. Nature 1980a; 287: 451–454
  • Chiodo L. A., Antelman S. M. Electroconvulsive shock: Progressive dopamine autoreceptor subsensitivity independent of repeated treatment. Science 1980b; 210: 799–801
  • Cimino M., Vantini G., Algeri S., Curatola G., Pezzoli C., Stramentinoli G. Age-related modification of dopaminergic and β-adrenergic receptor system: Restoration to normal activity by modifying membrane fluidity with S-adenosyl methionine. Life Sciences 1984; 34: 2029–2039
  • Clements-Jewery S. The development of cortical β-adrenoceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserin. Neuropharmacology 1978; 17: 779–781
  • Cohen M. R., Pickar D., Extein I., Gold M. S., Sweeney D. R. Plasma Cortisol and β-endorphin immunoreactivity in nonmajor and major depression. American Journal of Psychiatry 1984; 141: 628–632
  • Cohen R. M., Campell I. C, Dauphin M., Tallman J. F., Murphy D. L. Changes in α- and β-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. Neuropharmacology 1982a; 21: 293–298
  • Cohen R. M., Ebstein R. P., Daly J. W., Murphy D. L. Chronic effects of a monoamine oxidase-inhibiting antidepressant: Decreases in functional α-adrenergic autoreceptors precede the decrease in norepinephrine-stimulated cyclic adenosine 3′:5′-monophosphate systems in rat brain. Journal of Neurosciences 1982b; 2: 1588–1595
  • Cohn C. K., Dunner D. L., Axelrod J. Reduced catechol-O-methyltransferase activity in red blood cells of depressed women with primary affective disorders. Science 1970; 170: 1323–1324
  • Consolo S., Ladinsky H., Forloni G. L., Grombi P. Modulation of the hippocampal β-adrenoceptor population by lesion of the serotonergic raphe-hippocampal pathway of rats. Life Sciences 1982; 30: 1113–1120
  • Coper H., Fahndrich E., Gelbert A., Helmchen H., Honecker H., Mulleroerlinghausen B., Pietzcker A. Depression and monoamine oxidase. Progress in Neuropsychopharmacology 1979; 3: 441–463
  • Coppen A., Rama Rao V. A., Ruthven C. R. J., Goodwin B. L., Sandler M. Urinary 4-hydroxy-3-methoxyphenylglycol is not a predictor for clinical response to amitriptyline in depressive illness. Psychopharmacology 1979; 64: 95–97
  • Costa E. Perspectives in the molecular mechanisms of antidepressant action. Typical and atypical antidepressants: Molecular mechanisms, E. Costa, G. Racagni. Raven Press, New York, 21–26
  • Creese I., Sibley I. Receptor adaptations to centrally acting drugs. Annual Review of Pharmacology and Toxicology 1981; 21: 357–391
  • Crews F. T., Paul S. M., Goodwin F. K. Acceleration of β-receptor desensitization in combined administration of antidepressants and phenoxybenzamine. Nature 1981; 290: 787–789
  • Daiguji M., Meltzer H. Y., Tong C, U'Prichard D. C, Young M., Kravitz H. α2-Adrenergic receptors in platelet membranes of depressed patients: No change in number or 3H-yohimbine affinity. Life Sciences 1981; 29: 2059–2064
  • Davidson J. R. T., McLeod M. N., Turnbull C. D., White H. L., Feuer E. J. Catechol-O-methyltransferase activity and classification of depression. Biological Psychiatry 1979; 14: 937–942
  • Davidson J. R. T., McLeod M. N., Turnbull C. D., White H. L., Feuer E. J. Platelet monoamine oxidase activity and the classification of depression. Archives of General Psychiatry 1980; 37: 771–773
  • Deguchi T., Axelrod J. Superinduction of serotonin N-acetyl-transferase and supersensitivity of adenyl cyclase to catecholamines in denervated pineal gland. Molecular Pharmacology 1973; 9: 612–618
  • Delay J., Laine B., Buisson J. F. Note concernant Taction de 1 'isonicotinylhydrazide dans le traitement des etats depressifs. Annals of Medicine and Psychology 1952; 110: 689
  • De Montigney C., Aghajanian G. K. Tricyclic antidepressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 1978; 202: 1303–1306
  • Depue R. A., Monroe S. M., Shcckman S. L. The psychobiology of human disease: Implications for conceptualizing the depressive disorders. The psychobiology of the depressive disorders: Implications for the effects of stress, R. A. Depue. Academic Press, New York 1979; 3–20
  • Dumbrille-Ross A., Tang S., Seeman P. High affinity binding of [3H]mianserin to rat cerebral cortex. European Journal of Pharmacology 1980; 68: 395–396
  • Dunner D. L., Cohn C. K., Gershon E. S., Goodwin F. K. Differential catechol-0-methyltransferase activity in unipolar and bipolar illnesses. Archives of General Psychiatry 1971; 25: 348–353
  • Ebstein R., Belmaker R. H., Benbenisty D., Rimon R. Electrophoretic pattern of red blood cell catechol-O-methyltransferase in schizophrenic and manic-depressive illness. Biological Psychiatry 1976; 11: 613–623
  • Eccles J. C. Conduction and synaptic transmission in the nervous system. Annual Review of Physiology 1948; 10: 93–116
  • Ellis E. F., Rosenblum W. I., Birkle D. L., Wright K. F., Traweek D. L., Saady J. J., Choi S. C. The effect of tranylcypromine on levels of 6-keto-PGFi and other prostaglandins in brain and mesentery of the mouse. Artery 1982; 10: 454–464
  • Enna S. J., Gallagher J. P. Biochemical and electrophysiological characteristics of mammalian GABA receptor. International Reviews of Neurobiology 1983; 24: 181–212
  • Enna S. J., Mann E., Kendal D., Stancel G. M. Effect of chronic antidepressant administration on brain neurotransmitter receptor binding. Antidepressants: Neurochemical, behavioral and clinical perspectives, S. J. Enna, J. B. Malick, E. Richelson. Raven Press, New York 1981; 91–103
  • Fawcett J. Depression at the biochemical level. Psychiatric Annals 1980; 10: 362–368
  • Flynn D. D., Kloog Y., Potter L. T., Axelrod J. Enzymatic methylation of the membrane-bound nicotinic acetylcholine receptor. Journal of Biological Chemistry 1982; 257: 9513–9517
  • Friedhoff A. J. Receptor sensitivity modification (RSM)–a new paradigm for the potential treatment of some hormonal and transmitter disturbances. Comprehensive Psychiatry 1977; 18: 309–317
  • Friedman E., Dallob A. Enhanced serotonin receptor activity after chronic treatment with imipramine or amitriptyline. Communications in Psychopharmacology 1979; 3: 89–92
  • Fries E. D. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. New England Journal of Medicine 1954; 251: 1006–1008
  • Fuxe K., Ogren S.-O., Agnati L. F., Benfenati F., Fredholm B., Andersson K., Zini I., Eneroth P. Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology 1983; 22: 389–400
  • Gallager D. W., Bunney W. E., Jr. Failure of chronic lithium treatment to block tricyclic anti-depressants-induced 5-HT supersensitivity. Naunyn-Schmiedeberg's Archives for Pharmacology 1979; 307: 129–133
  • Garcia-Sevilla J. A., Zis A., Hollingworth P. J., Greden J. F., Smith C. B. Platelet α2-adrenergic receptors in major depressive disorders. Archives of General Psychiatry 1981; 38: 1327–1333
  • Gershon E. S. The search for genetic markers in affective disorders. Psychopharmacology: A generation of progress, M. A. Lipton, A. DiMascia, K. F. Killam. Raven Press, New York 1978; 1197–1212
  • Gershon E. S., Jonas W. Z. Erythrocyte soluble catechol-O-methyltransferase activity in primary affective disorders. Archives of General Psychiatry 1975; 32: 1351–1356
  • Gershon E. S., Bunney W. E., Jr., Leckman J., Van Eerdewegh M., DeBauche B. The inheritance of affective disorders: A review of data and of hypotheses. Behavioral Genetics 1976; 6: 227–261
  • Gershon E. S., Beimaker R. H., Ebstein R., Jonas W. Z. Plasma MAO-activity unrelated to genetic vulnerability to primary affective illness. Archives ofGeneral Psychiatry 1977; 34: 731–734
  • Gold P. W., Ballenger J. C, Weingartner H., Goodwin F. K., Post R. M. Effects of 1-desamo-8-D-arginine vasopressin on behavior and cognition in primary affective disorder. Lancet 1979; 2: 992–994
  • Goodwin F. K., Bunney W. E., Jr. Depressions following reserpine: A re-evaluation. Seminars in Psychiatry 1971; 3: 435–446
  • Goodwin F. K., Post R. M., Sack R. L. Clinical evidence for neurochemical adaptation to psychotropic drugs. Neurobiological mechanisms of adaptation and behavior, A. J. Mandell. Raven Press, New York 1975; 33–45
  • Green A. R., Sant K., Bowdler J. M., Cowen P. J. Further evidence for a relationship between changes in GABA concentration in rat brain and enhanced monoamine-mediated behavioral responses following repeated electroconvulsive shock. Neuropharmacology 1982; 21: 981–984
  • Green J. P., Maayani S. Tricyclic antidepressant drugs block histamine Ha receptors in brain. Nature 1977; 269: 163–165
  • Gross G., Brodde O. E., Schumann H. J. Decreased number of adrenoceptors in cerebral cortex of hypothyroid rats. European Journal of Pharmacology 1980; 61: 191–194
  • Heron D., Hershkowitz M., Shinitzky M., Samuel D. The lipid fluidity of synaptic membranes and the binding of serotonin and opiate ligands. Neurotransmitters and their receptors, Y. Dudai, U. Littauer, I. Silman, V. I. Teichberg, Z. Vogel. John Wiley, New York 1980a; 125
  • Heron D. S., Shinitzky M., Hershkowitz M., Sammuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proceedings of the National Academy of Sciences U.S.A. 1980b; 77: 7463–7467
  • Heron D., Israel M., Hershkowitz M., Sammuel D. Lipid induced modulation of opiate receptors in mouse brain membranes. European Journal of Pharmacology 1981; 72: 361–364
  • Heron D. S., Shinitzky M., Zamir N., Samuel D. Adaptive modulations of brain membrane lipid fluidity in drug addiction and denervation supersensitivity. Biochemical Pharmacology 1982a; 31: 2435–2438
  • Heron D. S., Shinitzky M., Samuel D. Alleviation of drug withdrawal symptoms by treatment with a potent mixture of natural lipids. European Journal of Pharmacology 1982b; 83: 253–261
  • Hershkowitz M., Heron D. S., Samuel D., Shinitzky M. The modulation of protein phosphorylation and receptor binding in synaptic membranes by changes in lipid fluidity: Implications for aging. Progress in Brain Research 1982; 56: 419–434
  • Hirata F., Axelrod J. Phospholipid methylation and the transmission of biological signals through membranes. Science 1980; 209: 1082–1090
  • Hokin-Neaverson M., Spiegel D. A., Lewis W. C. Deficiency of erythrocyte sodium pump activity in bipolar manic-depressive psychosis. Life Sciences 1974; 15: 1739–1748
  • Holmes R. P., Mahfauz M., Travis B. D., Yoss N. L., Keenan M. J. The effect of membrane lipid composition on the permeability of membranes to Ca2+. Annals of the New York Academy of Science 1983; 414: 44–50
  • Honegger U. E-, Roscher A. A., Wiesmann U. N. Evidence for lysosomotropic action of des-ipramine in cultured human fibroblasts. Journal of Pharmacology and Experimental Therapeutics 1983; 225: 436–441
  • Hornykiewicz O. Brain catecholamines in schizophrenia–a good case for noradrenaline. Nature 1982; 299: 484–486
  • Houslay M. D., Stanley K. K. Dynamics of biological membranes: Influence of synthesis, structure and function. Wiley, New York 1982
  • Houslay M. D., Gordon L. M. The activity of adenylate cyclase is regulated by the nature of its lipid environment. Current Topics in Membrane Transport 1983; 18: 179–231
  • Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Research 1975; 88: 295–308
  • Hughes J., Smith T. W., Kosterlitz H. W., Fothergill L., Morgan B. A., Morris H. R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975a; 258: 577–579
  • Hughes J., Smith T., Morgan B., Fothergill L. Purification and properties of enkephalin–the possible endogenous ligand for the morphine receptor. Life Sciences 1975b; 16: 1753–1758
  • Hullin R. P. Biochemistry of affective disorders. Journal of International Medical Research 1977; 5: 140–145
  • Jahr C. E., Nicoll R. A. Noradrenergic modulation of dendrodendritic inhibition in the olfactory bulb. Nature 1982; 297: 227–229
  • Janowsky A., Steranka L. R., Gillespie D. D., Sulser F. Role of neuronal signal input in the down-regulation of central noradrenergic receptor function by antidepressant drugs. Journal of Neurochemistry 1982; 39: 290–292
  • Jimmerson D. C, Post R. M., Stoddard F. R., Gillin J. C, Bunney W. E., Jr. Preliminary trial of the noradrenergic agonist clonidine in psychiatric patients. Biological Psychiatry 1980; 15: 45–57
  • Johnson D. A., Cooke R., Loh H. H. Effect of opiate agonists and antagonists on lipid fluidity. Molecular Pharmacology 1979a; 16: 154–162
  • Johnson D. A., Lee N. M., Cooke R. Adaptation to ethanol- induced fluidization of brain lipid bilayers. Drug and Alcohol Dependence 1979b; 4: 197–202
  • Johnson R. W., Reisine T., Spotnitz S., Wiech N., Ursillo R., Yamamura H. I. Effects of desipramine and yohimbine on α2 and α1 adrenoreceptor sensitivity. European Journal of Pharmacology 1980; 67: 123–127
  • Kafka M. S., Wirz-Justice A., Naber D., Wehr T. A. Orcadian acetylcholine receptor rhythm in rat brain and its modification by imipramine. Neuropharmacology 1981; 20: 421–425
  • Kandei E. R., Schwartz J. H. Molecular biology of learning: Modulation of transmitter release. Science 1982; 218: 433–443
  • Kanno K., Sasaki Y. Interaction of psychotropic drugs with phospholipids. Biochemical Pharmacology 1982; 31: 2977–2981
  • Kanof P. D., Greengard P. Brain histamine receptor as targets for antidepressant drugs. Nature 1978; 272: 329–333
  • Karliner J. S., Motulsky H. J., Insel P. A. Apparent “down- regulation” of human platelet alpha2-adrenergic receptors is due to retained agonist. Molecular Pharmacology 1982; 21: 36–43
  • Katz B., Thesleff S. A study of desensitization produced by acetylcholine at the motor endpiate. Journal of Physiology (London) 1957; 138: 63–80
  • Kellar K. J., Cascio C. S., Bergstrom D. A., Butler J. A., Iadarola P. Electroconvulsive shock and reserpine: Effects on β-adrenergic receptors in rat brain. Journal of Neurochemistry 1981; 37: 830–836
  • Kimelberg H. K. The influence of membrane fluidity on the activity of membrane-bound enzymes. Dynamic aspects of cell surface organization, G. Poste, G. L. Nicolson. Elsevier, Amsterdam 1977; 205–293
  • Kinnier W. J., Chuang D.-M., Gwynn G., Costa E. Characteristics and regulation of high affinity [3H]imipramine binding to rat hippocampal membranes. Neuropharmacology 1981; 20: 411–419
  • Kline N. S. Present status of psychopharmacological research hearings before the subcommittee on appropriations. U.S. Government Printing Office, Washington, D.C. 1957, US Senate, 85 Congress First Session on H. R. 6287
  • Koide T., Matsushita H. An enhanced sensitivity of muscarinic cholinergic receptor associated with dopaminergic receptor subsensitivity after chronic antidepressant treatment. Life Sciences 1981; 28: 1139–1145
  • Koss M. C., Christensen H. D. Evidence for central post-synaptic action of clonidine. Naunyn-Schmiedeberg's Archives for Pharmacology 1979; 307: 45–50
  • Kufferle B., Grunberger J. Early clinical double-blind study with S-adenosyl-L-methionine: A new potential antidepressant. Typical and atypical antidepressants: Clinical practice, E. Costa, G. Racagni. Raven Press, New York 1982; 175–180
  • Kuhn R. The treatment of depressive states with G-22355 (Imipramine Hydrochloride). American Journal of Psychiatry 1958; 115: 459–464
  • Langer S. Z., Briley M. S., Raisman R., Henery J. F., Morselli P. L. Specific 3H-imipramine binding in human platelets: Influence of sex and age. Naunyn-Schmiedeberg's Archives for Pharmacology 1980; 313: 189–194
  • Langer S. Z., Raisman R. Binding of [3H]imipramine and [3H] desipramine as biochemical tools for studies in depression. Neuropharmacology 1983; 22: 407–413
  • Leckman J. E., Gershon E. S., Nichols A. S., Murphy D. L. Reduced MAO-activity in first degree relatives of individuals with bipolar affective disorders. Archives of General Psychiatry 1977; 34: 601–606
  • LeFur G., Phan T., Burgevin M. C, Flamier A., Mitrani N., Marquis F., Lozefczak F., Uzan A. A subacute treatment with 1- methionine induces an increase in the number of 3H-spiperone binding sites in the striatum of the rat. Life Sciences 1983; 32: 2321–2328
  • Littleton I. M. Cell-membrane lipids in ethanol-tolerance and -dependence. Biochemistry Society Transactions 1983; 11: 61–62
  • Long J. B., Youngblood W. Y., Kizer J. S. Regional differences in the response of serotonergic neurons in rat CNS to drugs. European Journal of Pharmacology 1983; 88: 89–97
  • Loomer H. P., Saunders J. C., Kline N. S. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. American Psychiatric Association Psychiatric Research Reports 1957; 8: 129
  • Maas J. W., Hattox S. E., Green N. M., Landis D. H. 3-Methoxy- 4-hydroxyphenethyleneglygol production by human brain in vivo. Science 1979; 205: 1025–1027
  • Maeda K., Kato U., Ohgo S., Chihara K. Growth hormone and prolactin release after injection of TRH in patients with depression. Journal of Clinical Endocrinology and Metabolism 1975; 40: 501–505
  • Maggi A., U'Prichard D. C., Enna S. I. Differential effects of antidepressant treatment on brain monoaminergic receptors. European Journal of Pharmacology 1980; 61: 91–98
  • Maley B., Elde R. The ultrastructural localization of serotonin immunoreativity within the nucleus of the solitary tract of the cat. Journal of Neuroscience 1982; 2: 1499–1506
  • Mandell A. J., Knapp S. A neurobiological model for the symmetrical prophylactic action of lithium in bipolar affective disorder. Pharmakopsychiatria 1976; 9: 116–126
  • Mann E., Enna S. J. Neurochemical and behavioral correlates of antidepressant drug action. Life Sciences 1982; 30: 1653–1661
  • Maura G., Gemignani A., Raiteri M. Noradrenaline inhibits central serotonin release through alpha2-adrenoceptors located on serotonergic nerve terminals. Naunyn-Schmiedeberg's Archives for Pharmacology 1982; 320: 272–274
  • McGeer P. L., McGeer E. G. Chemistry of mood and emotion. Annual Review of Psychology 1980; 31: 273–307
  • McNamara J. O. Selective alterations of regional /3-adrenergic receptor binding in the kindling model of epilepsy. Experimental Neurology 1978; 61: 582–591
  • Mendels J., Frazer A. Alternations in cell membrane activity in depression. American Journal of Psychiatry 1974; 131: 1240–1246
  • Menkes D. B., Aghajanian G. K., Gallager D. W. Chronic antidepressant treatment enhancesagonist affinity of brain α1 adrenoceptors. European Journal of Pharmacology 1983; 87: 35–41
  • Meyerson L. R., Wennogie L. P., Abel M. S., Coupet J., Lippa A. S., Rauh C. E., Beer B. Human brain receptor alterations in suicide victims. Pharmacology Biochemistry and Behavior 1982; 17: 159–163
  • Mishra R., Janowsky A., Sulser F. Action of mianserin and zimelidine on the norepinephrine receptor coupled adenylate cyclase system in brain: Subsensitivity without reduction in β-adrenergic receptor binding. Neuropharmacology 1980; 19: 983–987
  • Mogilnicka E., Arbilla S., Depoortere H., Langer S. Z. Rapid- eye-movement sleep deprivation decreases the density of 3H-dihydroalprenolol and 3H-imipramine binding sites in the rat cerebral cortex. European Journal of Pharmacology 1980; 65: 289–292
  • Mohler H., Okada T. Benzodiazepine receptor: Demonstration in the central nervous system. Science 1977; 198: 849–851
  • Moore R. Y., Bloom F. E. Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems. Annual Review of Neuroscience 1979; 2: 113–168
  • Muller J. C, Pryor W. W., Gibbons J. E., Orgain E. S. Depressions and anxiety during Rauwolfia therapy. Journal of the American Medical Association 1955; 159: 836–840
  • Murphy D. L., Belmaker R., Wyatt R. J. Monoamine oxidase in schizophrenia and other behavioral disorders. Journal of Psychiatry Research 1974; 11: 221–247
  • Naber D., Wirz-Justice A., Kafka M. S., Wehr T. A. Dopamine receptor binding in rat striatum : Ultradian rhythm and its modification by chronic imipramine. Psychopharmacology 1980; 68: 1–5
  • Naylor G. J., Smith A. H. Defective genetic control of sodium- pump density in manic depressive psychosis. Psychological Medicine 1981; 11: 257–263
  • Nies A., Robinson D. S., Ravaris C. L., Davis J. M. Amines and monoamine oxidase in relation to aging and depression. Psychosomatic Medicine 1971; 33: 470, (Abstract).
  • O'Brien R. A., Spirit N. M., Horst W. D. Antidepressant receptor binding in brain. Society of Neuroscience 1978, Abstract 136.6
  • Olpe H.-R. Differential effects of clomipramine and clorgyline on the sensitivity of cortical neurons to serotonin: Effect of chronic treatment. European Journal of Pharmacology 1981; 69: 375–377
  • Palkovits M., Raisman R., Briley M., Langer S. Z. Regional distribution of [3H]imipramine binding in rat brain. Brain Research 1981; 210: 493–498
  • Pare C. M. B., Sandler M. J. A clinical and biochemical study of a trial of iproniazid in the treatment of depression. Journal of Neurology, Neurosurgery and Psychiatry 1959; 22: 247–251
  • Passarelli F., de Carolis Scotti A. Effects of chronic treatment with imipramine on the behavioral and electroencephalographic modifications induced by clonidine in the rat. Neuropharmacology 1982; 21: 591–593
  • Paul S. M., Rehavi M., Skolnik P., Ballenger J. C., Goodwin F. K. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin “transporter”. Archives of General Psychiatry 1981; 38: 315–317
  • Peroutka S. J., Snyder S. H. Multiple serotonin receptors: Differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Molecular Pharmacology 1979; 16: 687–699
  • Peroutka S. J., Snyder S. H. Long-term antidepressant treatment lowers spiroperidol-labeled serotonin receptors. Science 1980a; 21: 88–90
  • Peroutka S. J., Snyder S. H. Regulation of serotonin (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. Journal of Pharmacology and Experimental Therapeutics 1980b; 215: 582–587
  • Peroutka S. J., Snyder S. H. [3H]mianserin: Differential labeling of serotonina and histamine1 receptors in rat brain. Journal of Pharmacology and Experimental Therapeutics 1981; 216: 142–148
  • Peroutka S. J., Lebovitz R. M., Snyder S. H. Two distinct central serotonin receptors with different physiological functions. Science 1981; 212: 827–829
  • Perry E. K., Marshall E. F., Blessed G., Tomlinson B. E., Perry R. H. Decreased imipramine binding in the brains of patients with depressive illness. British Journal of Psychiatry 1983; 142: 188–192
  • Pert C. B., Snyder S. H. Opiate receptor: Demonstration in nervous tissue. Science 1973; 179: 1011–1014
  • Pilc A., Vetulani J. Attenuation by chronic imipramine treatment of [3H]clonidine binding to cortical membranes and of clonidine-induced hypothermia: The influence of central chemo-sympathectomy. Brain Research 1982; 238: 499–504
  • Plenge P., Mellerup E. T. 3H-imipramine high affinity binding sites in rat brains: Effects of imipramine and lithium. Psychopharmacology 1982; 77: 94–97
  • Post R. M., Kotin J., Goodwin F. K. The effects of cocaine on depressed patients. American Journal of Psychiatry 1974; 131: 511–517
  • van Praag H. M. The significance of biochemical factors in the diagnosis of depressions: I Biochemical variables. Comprehensive Psychiatry 1982; 23: 124–135
  • van Praag H. M., de Haan S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatric Research 1980; 3: 75–83
  • van Praag H. M., Korf J. Endogenous depressions with and without disturbances in 5-hydroxy-tryptamine metabolism: A biochemical classification. Psychopharmacology 1971; 19: 148–152
  • Racagni G., Mocchetti I., Caldfrini G., Battistella A., Brunello N. Temporal sequence of changes in central noradrenergic system of rat after prolonged antidepressant treatment: Receptor densitization and neurotransmitter interactions. Neuropharmacology 1983; 22: 415–424
  • Rainbow T. C, Biegon A., McEwen B. S. Autoradiographic localization of imipramine binding in rat brain. European Journal of Pharmacology 1982; 77: 363–364
  • Raisman R., Briley M., Langer S. Z. Specific tricyclic antidepressant binding sites in rat brain. Nature 1979a; 281: 148–150
  • Raisman R., Briley M., Langer S. Z. High-affinity 3H- imipramine binding in rat cerebral cortex. European Journal of Pharmacology 1979b; 54: 307–308
  • Raisman R., Briley M. S., Langer S. Z. Specific tricyclic antidepressant binding sites in rat brain characterized by high affinity 3H-imipramine binding. European Journal of Pharmacology 1980; 61: 373–380
  • Raisman R., Briley M. S., Langer S. Z., Sechter D., Zarifian E. High affinity 3H-imipramine binding in platelets from healthy volunteers and untreated and treated depressed patients. Psychopharmacology 1981; 75: 368–371
  • Raisman R., Briley M. S., Bouchani F., Sechter D., Zarifian E., Langer S. Z. 3H-imipramine binding and serotonin uptake in platelets from untreated depressed patients and control volunteers. Psychopharmacology 1982; 77: 332–335
  • Raiteri M., Maura G., Versace P. Functional evidence for two steroechemically different alpha-2 adrenoceptors regulating central norepinephrine and serotonin release. Journal of Pharmacology and Experimental Therapeutics 1982; 224: 679–684
  • Ramsey T. A., Frazer A., Mendels J. Plasma and erythrocyte cations in affective illness. Neuro-psychobiology 1979; 5: 1–10
  • Rehavi M., Sokolovsky M. Multiple binding sites of tricyclic antidepressant drugs to mammalian brain receptors. Brain Research 1978; 149: 525–529
  • Rehavi M., Ramot O., Yavetz B., Sokolovsky M. Amitriptyline: Long-term treatment elevates a-adrenergic and muscarinic receptor binding in mouse brain. Brain Research 1980; 194: 443–453
  • Reid R. L., Yen S. S. Premenstrual syndrome. American Journal of Obstetrics and Gynecology 1980; 139: 85–104
  • Reinhard J. F., Roth R. H. Noradrenergic modulation of serotonin synthesis and metabolism: 1. Inhibition by clonidine in vivo. Journal of Pharmacology and Experimental Therapeutics 1982; 221: 541–546
  • Reisine T., Soubrie P. Loss of rat cerebral cortical opiate receptors following chronic desipramine treatment. European Journal of Pharmacology 1982; 77: 39–44
  • Richardson J. S., Cowan N., Hartman R., Jacobowitz D. M. On the behavioral and neurochemical actions of 6-hydroxydopa and 5, 6-dihydroxytryptamine in rats. Research Communications in Chemical Pathology and Pharmacology 1974; 8: 29–45
  • Richelson E. Tricyclic antidepressants block histamine Hi receptors of mouse neuroblastoma cells. Nature 1978; 274: 176
  • Risch S. C, Kalin N. H., Murphy D. L. Pharmacological challenge strategies: Implications for neurochemical mechanisms in affective disorders and treatment approaches. Journal of Clinical Psychopharmacology 1981; 1: 238–243
  • Ritzmann R. F., Springer A. Age differences in brain sensitivity and tolerance to ethanol in mice. Age 1980; 3: 15
  • Rosenblatt J. E., Pert C. B., Tallman J. F., Pert A., Bunney W. E., Jr. The effect of imipramine and lithium on a- and /8-receptor binding in rat brain. Brain Research 1979; 160: 186–191
  • Rubinow D. R., Post R. M., Gold P. W. Cortisol hypersecretion and cognitive impairment in depression. Archives of General Psychiatry 1984; 41: 279–283
  • Sachar E. J., Baron M. The biology of affective disorders. Annual Review of Neuroscience 1979; 2: 505–518
  • Savage D. D., Frazer A., Mendels J. Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain. European Journal of Pharmacology 1979; 58: 87–88
  • Savage D. D., Mendels J., Frazer A. Decrease in [3H]-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists. Neuropharmacology 1980; 19: 1063–1070
  • Schildkraut J. J. Catecholamine hypothesis of affective disorders: Review of supporting evidence. American Journal of Psychiatry 1965; 122: 509–522
  • Schildkraut J. J., Kety S. S. Biogenic amines and emotions. Science 1967; 156: 21–30
  • Schildkraut J. J., Orsulak P. J., Schatzberg A. F., Gudeman J. E., Cole J. O., Rohde W. A., LaBrie R. A. Towards a biochemical classification of depressive disorders. I: Difference in urinary MHPG and other catecholamine metabolites in clinically defined subtypes of depression. Archives of General Psychiatry 1978; 35: 1427–1433
  • Schottstaedt W. W., Grace W. J., Wolff H. G. Life situations, behavior attitudes, emotions and renal excretion of fluid and electrolytes. IV: Situations associated with retention of water, sodium and potassium. Journal of Psychosomatic Research 1956; 1: 287–291
  • Scott J. A., Crews F. T. Rapid decrease in rat brain beta adrenergic receptor binding during combined antidepressant a2 antagonist treatment. Journal of Pharmacology and Experimental Therapeutics 1983; 224: 640–646
  • Sedvall G., Fryo B., Gullberg B. Relationships in healthy volunteers between concentration of monoamine metabolites in cerebrospinal fluid and family history of psychiatric morbidity. British Journal of Psychiatry 1980; 136: 366–374
  • Segal D. S., Kuczenski R., Mandell A. Theoretical implications of drug-induced adaptive regulation for a biogenic amine hypothesis of affective disorder. Biological Psychiatry 1974; 9: 147–159
  • Segal M. Serotonergic innervation of the locus coeruleus from the dorsal raphe and its action of responses to noxious stimuli. Journal of Physiology (London) 1979; 286: 401–415
  • Segal M. Regional differences in neuronal response to 5-HT: Intracellular studies in hippocampal slices. Journal of Physiology (Paris') 1981a; 77: 373–375
  • Segal M. The action of serotonin in the rat hippocampus. Serotonin: Current aspects of neurochemistry and function, B. Haber, S. Gabay, M. R. Issidorides, S. G.A. Alivisatos. Plenum Press, New York 1981b; 375–390
  • Segawa T., Mituta T., Nomura Y. Modifications of central 5-hydroxytryptamine binding sites in synaptic membranes from rat brain after long-term administration of tricyclic antidepressants. European Journal of Pharmacology 1979; 58: 75–83
  • Serra G., Argiolas F., Fadda F., Gessa G. L. Hyposensitivity of dopamine “autoreceptors” induced by chronic administration of tricyclic antidepressants. Pharmacological Research Communications 1980; 12: 619–624
  • Sette M., Raisman R., Briley M, Langer S. Z. Localization of tricyclic antidepressant binding sites on serotonin nerve terminals. Journal of Neurochemistry 1981; 37: 40–42
  • Sgaragli G. P., Corte L. D., Gremigni D. Chlorimipramine-induced phospholipidosis: Biochemical and pharmacokinetic observations in the rat. Pharmacological Research Communications 1983; 15: 231–246
  • Shinitzky M., Barenholz Y. Fluidity parameters of lipid regions determined by fluorescence polarization. Biochimica et Biophysica Acta 1978; 515: 367–394
  • Shopsin B., Wilk S., Gershon S., RofTman M., Goldstein M. Collaborative psychopharma-cologic studies exploring catecholamine metabolism in psychiatric disorders. Frontiers in catecholamine research, E. Usdin, S. Snyder. Pergamon Press, New York 1974; 1173–1179
  • Shore P. A., Brodie B. B. Influence of various drugs on serotonin and norepinephrine in the brain. Psychotropic drugs, S. Garattini, U. Ghetti. Elsevier, Amsterdam 1957; 423–427
  • Shore P. A., Silver S. L., Brodie B. B. Interaction of reserpine, serotonin and lysergic acid diethylamide in brain. Science 1955; 122: 284–285
  • Siever L. J., Cohen R. M., Murphy D. L. Antidepressants and α2 adrenergic autoreceptor desensitization. American Journal of Psychiatry 1981; 138: 681–682
  • Siever L. J., Uhde T. W. New studies and perspectives on the noradrenergic receptor system in depression: Effects of the α2-adrenergic agonist clonidine. Biological Psychiatry 1984; 19: 131–156
  • Silverman J. S., Silverman J. A., Eardley D. A. Do maladaptive attitudes cause depression?. Archives of General Psychiatry 1984; 41: 28–30
  • Simon E. J., Hiller J. M., Edeiman I. Stereospecific binding of the potent narcotic analgesic [3H]etorphine to rat-brain homogenate. Proceedings of the National Academy of Science U.S.A. 1973; 70: 1947–1949
  • Sjoerdsma A., Smith T. E., Stevenson T. D., Udenfriend S. Metabolism of 5-hydroxytryptamine (serotonin) by monoamine oxidase. Proceedings of the Society of Experimental Biology and Medicine 1955; 89: 36–38
  • Smith C. B., Garcia-Sevilla J. A., Hollingsworth P. J. α2-adrenoreceptors in rat brain are decreased after long-term tricyclic antidepressant treatment. Brain Research 1981; 210: 413–418
  • Snyder S. H. Receptors, neurotransmitters and drug responses. New England Journal of Medicine 1979; 300: 465–472
  • Spyraki C., Fibiger H. C. Functional evidence of subsensitivity of noradrenergic α2 receptors after chronic despiramine treatment. Life Sciences 1980; 27: 1863–1867
  • Squires R. F., Braestrup C. Benzodiazepine receptors in rat brain. Nature 1977; 266: 732–734
  • Stanbury J. B., Wyngaarden J. B., Fredrickson D. S. The metabolic basis of inherited disease. McGraw-Hill, New York 1978
  • Stanley M., Virgilio J., Gershon S. Tritiated imipramine binding sites are decreased in frontal cortex of suicides. Science 1982; 216: 1337–1339
  • Stone E. A., Piatt J. E. Brain adrenergic receptors and resistance to stress. Brain Research 1982; 237: 405–414
  • Stone T. W., Taylor D. A. Antidepressant drugs potentiate suppression by adenosine of neuronal firing in rat cerebral cortex. Neuroscience Letters 1979; 11: 93–97
  • Sulser F. New perspectives on the mode of action of antidepressant drugs. Trends in Pharmacological Sciences 1979; 1: 92–94
  • Sulser F., Janowsky A. J., Okada F., Manier D. H., Mobley P. L. Regulation of the recognition and action function of the norepinephrine (NE) receptor-coupled adenylate cyclase system in brain: Implications for the therapy of depression. Neuropharmacology 1983; 22: 425–431
  • Sulser F., Vetulani J. The noradrenergic cyclic AMP generating system in the limbic forebrain: A functional postsynaptic norepinephrine receptor system and its modification by drugs which either precipitate or alleviate depression. Models in psychiatry and neurology, E. Usdin, I. Hanin. Pergamon Press, New York 1977; 189–199
  • Suranyi-Cadotte B. E., Wood P. L., Vasavan-Nair N. P., Schwartz G. Normalization of platelet 3[H] imipramine binding in depressed patients during remission. European Journal of Pharmacology 1982; 85: 357–358
  • Svensson J. H., Usdin R. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: Receptor mediation. Science 1978; 202: 1089–1091
  • Tran V. T., Lebovitz R, Toll L., Snyder S. H. [3H]Doxepin interactions with histamine Hi-receptor and other sites in guinea pig and rat brain homogenates. European Journal of Pharmacology 1981; 70: 501–509
  • Traskman L., Asberg M., Bertilsson L. Monoamine metabolite in CSF and suicidal behavior. Archives of General Psychiatry 1981; 38: 631–636
  • U'Prichard D. C, Greenberg D. A., Sheehan P. P., Snyder S. H. Tricyclic antidepressants: Therapeutic properties and affinity for α-noradrenergic receptor binding sites in the brain. Science 1978; 199: 197–198
  • U'Prichard D. C, Bechtel W. D., Rouot B. M., Snyder S. H. Multiple apparent alpha noradrenergic receptor binding sites in rat brain: Effects of 6-hydroxydopamine. Molecular Pharmacology 1979; 16: 47–60
  • van Zwieten P. A., Timmermans P. B. The role of central a-adrenoreceptors in the mode of action of hypotensive drugs. Trends in Pharmacological Sciences 1979; 1: 39–44
  • Vetulani J., Suiser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 1975; 257: 495–496
  • Vetulani J., Stawarz R. J., Suiser F. Adaptive mechanism of the noradrenergic cyclic AMP generating system in limbic forebrain of the rat: Adaptation to persistent changes in the availability of norepinephrine. Journal of Neurochemistry 1976a; 27: 661–666
  • Vetulani J., Stawarz R. J., Dingell J. U., Suiser F. A possible mechanism of action of antidepressant treatments. Naunyn-Schmeideberg's Archives of Pharmacology 1976b; 293: 109–114
  • Wagner H. R., Davies J. N. Decreased β-adrenergic responses in the female rat brain are eliminated by ovariectomy: Correlation of 3[H]dihydroalprenoloI binding and catecholamine stimulated cyclic AMP levels. Brain Research 1980; 201: 235–239
  • Wang R. Y., Aghajanian G. K. Correlative firing patterns of serotonergic neurons in rat dorsal raphe nucleus. Journal of Neuroscience 1982; 2: 11–16
  • Weiner N. Multiple factors regulating the release of norepinephrine consequent to nerve stimulation. Federation Proceedings 1979; 38: 2193–2202
  • Weissman M. M., Gershon E. S., Kidd K. K., Prusoff B. A., Leckman J. F., Dibble E., Hamovit J., Thompson W. D., Pauls D. L., Guroff J. J. Psychiatric disorders in the relatives of probands with affective disorders. Archives of General Psychiatry 1984; 41: 13–21
  • Williams M., Risley E. A., Robinson J. L. Chronic in vivo treatment with desmethylimipramine and mianserin does not alter adenosine A-1 radioligand binding in rat cortex. Neuroscience Letters 1983; 35: 47–51
  • Willner P. Dopamine and depression: A review of recent evidence. I. Empirical studies. Brain Research Reviews 1983a; 6: 211–224
  • Willner P. Dopamine and depression: A review of recent evidence. II. Theoretical approaches. Brain Research Reviews 1983b; 6: 225–236
  • Willner P. Dopamine and depression: A review of recent evidence. III. The effects of antidepressant treatments. Brain Research Reviews 1983c; 6: 237–246
  • Winokur G. Genetic markers in depressive disorders. Progress in Neuro-Psychopharmacology 1979; 3: 625–630
  • Wirz-Justice A., Krauchi K., Morimasa T., Willener R., Feer H. Orcadian rhythm of [3H] imipramine binding in the rat suprachiasmatic nuclei. European Journal of Pharmacology 1983; 87: 331–333
  • Wolf W. A., Kuhn D. M., Lovenberg W. Blood pressure responses to local application of serotonergic agents in the nucleus tractus solitarii. European Journal of Pharmacology 1981; 69: 291–299
  • Wong D. L., Zager E. L., Ciaranello R. D. Effects of hypophysectomy and dexamethasone administration on central and peripheral S-adenosylmethionine levels. Journal of Neuroscience 1982; 2: 758–764
  • Wood K., Coppen A. α2-adrenergic receptors in depression. Lancet 1982; 1: 1121–1122
  • Woodward D. J., Moises H. C, Waterhouse B. D., Hoffer B. J., Freedman R. Modulatory actions of norepinephrine in the central nervous system. Federation Proceedings 1979; 38: 2109–2116
  • Woolley D. W., Shaw E. Some neurophysiological aspects of serotonin. British Medical Journal 1954; 2: 122–126
  • Yasuhara H., Matsuo H., Sakamoto K., Ueda I. Mechanism of membrane stabilizing and lytic effects of tricyclic antidepressants. Japanese Journal of Pharmacology 1980; 30: 397–401
  • Yoshioka T., Inoue H., Hotta Y. Defective phospholipid metabolism in the retinular cell membrane of norpA (no receptor potential) visual transduction mutants of Drosophila. Biochemical and Biophysical Research Communications 1983; 111: 567–573
  • Zeller E. M., Barsky J. In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl- 2-isopropyl hydrazine. Proceedings of the Society for Experimental Biology and Medicine 1952; 81: 459–461
  • Zimmer G., Gross W., Mehler U., Dorn-Zachertz D. Membrane action of tricyclic drugs. Arzneimittel-ForschunglDrug Research 1980; 30: 221–228
  • Zis A. P., Goodwin F. K. Novel antidepressants and the biogenic amine hypothesis of depression. Archives of General Psychiatry 1979; 36: 1097–1107

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.